U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H24N6O2S
Molecular Weight 412.5104
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CERALASERTIB

SMILES

C[C@]1([H])COCCN1c2cc(C3(CC3)[S@](=N)(=O)C)nc(-c4cncc5c4cc[nH]5)n2

InChI

InChIKey=DTTJKLNXNZAVSM-JYCIKRDWSA-N
InChI=1S/C20H24N6O2S/c1-13-12-28-8-7-26(13)18-9-17(20(4-5-20)29(2,21)27)24-19(25-18)15-10-22-11-16-14(15)3-6-23-16/h3,6,9-11,13,21,23H,4-5,7-8,12H2,1-2H3/t13-,29-/m1/s1

HIDE SMILES / InChI

Molecular Formula C20H24N6O2S
Molecular Weight 412.5104
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Ceralasertib, previously known as AZD6738, a potent and selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase was developed as an anticancer agent. Prevention of ATR-mediated signaling leads to the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis. AZD6738 as a combination therapy participates in phase II clinical trials for the treatment of gastric adenocarcinoma and malignant melanoma (in combination with durvalumab). For the treatment of gastric and breast cancer in combination with carboplatin, or with olaparib or with MEDI4736. Combination of acalabrutinib and AZ6738 is used in phase II trials for patients with chronic lymphocytic Leukemia. Besides, AZD6738 participates in umbrella Phase II study in patients with metastatic non-small cell lung cancer (NSCLC) who have progressed on an anti-programmed cell death-1/anti-programmed cell death ligand 1 (anti-PD-1/PD-L1) containing therapy.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1 nM [IC50]
PubMed

PubMed

TitleDatePubMed
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
2015 Dec 29
AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.
2017 Apr

Sample Use Guides

AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Jun 26 13:57:04 UTC 2021
Edited
by admin
on Sat Jun 26 13:57:04 UTC 2021
Record UNII
85RE35306Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CERALASERTIB
INN   USAN  
Official Name English
ATR KINASE INHIBITOR AZD6738
Common Name English
4-(4-(1-((S(R))-S-METHYLSULFONIMIDOYL)CYCLOPROPYL)-6-((3R)-3-METHYL-4-MORPHOLINYL)-2-PYRIMIDINYL)-1H-PYRROLO(2,3-B)PYRIDINE
Systematic Name English
AZD-6738
Common Name English
CERALASERTIB [USAN]
Common Name English
CERALASERTIB [INN]
Common Name English
1H-PYRROLO(2,3-B)PYRIDINE, 4-(4-(1-((S(R))-S-METHYLSULFONIMIDOYL)CYCLOPROPYL)-6-((3R)-3-METHYL-4-MORPHOLINYL)-2-PYRIMIDINYL)-
Systematic Name English
CERALASERTIB [WHO-DD]
Common Name English
AZD6738
Code English
Classification Tree Code System Code
NCI_THESAURUS C155926
Created by admin on Sat Jun 26 13:57:04 UTC 2021 , Edited by admin on Sat Jun 26 13:57:04 UTC 2021
NCI_THESAURUS C129825
Created by admin on Sat Jun 26 13:57:04 UTC 2021 , Edited by admin on Sat Jun 26 13:57:04 UTC 2021
Code System Code Type Description
FDA UNII
85RE35306Z
Created by admin on Sat Jun 26 13:57:04 UTC 2021 , Edited by admin on Sat Jun 26 13:57:04 UTC 2021
PRIMARY
NCI_THESAURUS
C111993
Created by admin on Sat Jun 26 13:57:04 UTC 2021 , Edited by admin on Sat Jun 26 13:57:04 UTC 2021
PRIMARY
DRUG BANK
DB14917
Created by admin on Sat Jun 26 13:57:04 UTC 2021 , Edited by admin on Sat Jun 26 13:57:04 UTC 2021
PRIMARY
ChEMBL
CHEMBL3545178
Created by admin on Sat Jun 26 13:57:04 UTC 2021 , Edited by admin on Sat Jun 26 13:57:04 UTC 2021
PRIMARY
INN
10842
Created by admin on Sat Jun 26 13:57:04 UTC 2021 , Edited by admin on Sat Jun 26 13:57:04 UTC 2021
PRIMARY
CAS
1352226-88-0
Created by admin on Sat Jun 26 13:57:04 UTC 2021 , Edited by admin on Sat Jun 26 13:57:04 UTC 2021
PRIMARY
PUBCHEM
121596701
Created by admin on Sat Jun 26 13:57:04 UTC 2021 , Edited by admin on Sat Jun 26 13:57:04 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
ACTIVE MOIETY
Originator: AstraZeneca; Developer: AstraZeneca, Royal Marsden Hospital; Class: Antineoplastic, Morpholine, Pyrimidine, Small molecule; Mechanism of Action: ATR protein inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phases: Phase I/II for Gastric cancer, Non-small cell lung cancer, Solid tumours, Phase I for B cell lymphoma, Chronic lymphocytic leukaemia, Lymphoid leukaemia; Most Recent Events: 28 Dec 2015 Samsung Medical Center initiates a phase I trial in Solid tumours (Second-line therapy or greater, Combination therapy) in South Korea (NCT02630199), 18 Dec 2015 Samsung Medical Center plans a phase I trial in Cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in South Korea (NCT02630199), 01 Oct 2014 Phase-I/II clinical trials in Gastric cancer (Combination therapy, Late-stage disease) in United Kingdom (PO) (NCT02264678)